| European Federation of Internal Medicine

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News

Type: News Feed

Shared Decision-Making – Optimizing Decisions Through Clinical Expertise and Patient Preferences

Submitted by Aneta on 11 August 2026 - 15:39

The EFIM Early Career Group is pleased to invite you to an upcoming webinar exploring the role of shared decision-making in modern Internal Medicine.

Date: 10 September 2026
Time: 16:30 CET

Read more about Shared Decision-Making – Optimizing Decisions Through Clinical Expertise and Patient Preferences

Human medicines European public assessment report (EPAR): Zebinix, eslicarbazepine acetate, Date of authorisation: 21/04/2009, Revision: 34, Status: Authorised

Submitted by Anonymous (not verified) on 11 August 2026 - 13:24

Human medicines European public assessment report (EPAR): Zebinix, eslicarbazepine acetate, Date of authorisation: 21/04/2009, Revision: 34, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Zebinix, eslicarbazepine acetate, Date of authorisation: 21/04/2009, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 33, Status: Authorised

Submitted by Anonymous (not verified) on 11 August 2026 - 13:00

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 33, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 33, Status: Authorised

Fees for human medicines

Submitted by Anonymous (not verified) on 11 August 2026 - 10:43

Fees for human medicines

Read more about Fees for human medicines

Human medicines European public assessment report (EPAR): Usgena, ustekinumab, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised

Submitted by Anonymous (not verified) on 11 August 2026 - 9:54

Human medicines European public assessment report (EPAR): Usgena, ustekinumab, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Usgena, ustekinumab, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 11 August 2026 - 9:19

Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 12, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 12, Status: Authorised

Clinical Trials Information System (CTIS): Walk-in clinic October 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 October 2026, 16:00 (CEST) to 7 October 2026, 17:00 (CEST)

Submitted by Anonymous (not verified) on 11 August 2026 - 8:36

Clinical Trials Information System (CTIS): Walk-in clinic October 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 October 2026, 16:00 (CEST) to 7 October 2026, 17:00 (CEST)

Read more about Clinical Trials Information System (CTIS): Walk-in clinic October 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 October 2026, 16:00 (CEST) to 7 October 2026, 17:00 (CEST)

HMPC: overview of assessment work - priority list

Submitted by Anonymous (not verified) on 11 August 2026 - 7:26

HMPC: overview of assessment work - priority list

Read more about HMPC: overview of assessment work - priority list

Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 11 August 2026 - 7:18

Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 4, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 4, Status: Authorised

European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Shared Decision-Making – Optimizing Decisions Through Clinical Expertise and Patient Preferences

Human medicines European public assessment report (EPAR): Zebinix, eslicarbazepine acetate, Date of authorisation: 21/04/2009, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 33, Status: Authorised

Fees for human medicines

Human medicines European public assessment report (EPAR): Usgena, ustekinumab, Date of authorisation: 17/11/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 12, Status: Authorised

Clinical Trials Information System (CTIS): Walk-in clinic October 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 7 October 2026, 16:00 (CEST) to 7 October 2026, 17:00 (CEST)

HMPC: overview of assessment work - priority list

Human medicines European public assessment report (EPAR): Yesintek, ustekinumab, Date of authorisation: 14/02/2025, Revision: 4, Status: Authorised

Newsletters

Latest Newsletters

You are here

Newsletters

Latest Newsletters